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Background: Palmitoylation is a 16-carbon lipid post-translational modification that increases protein hydrophobicity.
This form of protein fatty acylation is emerging as a critical regulatory modification for multiple aspects of cellular
interactions and signaling. Despite recent advances in the development of chemical tools for the rapid identification
and visualization of palmitoylated proteins, the palmitoyl proteome has not been fully defined. Here we sought to
identify and compare the palmitoylated proteins in murine fibroblasts and dendritic cells.
Results: A total of 563 putative palmitoylation substrates were identified, more than 200 of which have not been
previously suggested to be palmitoylated in past proteomic studies. Here we validate the palmitoylation of several new
proteins including Toll-like receptors (TLRs) 2, 5 and 10, CD80, CD86, and NEDD4. Palmitoylation of TLR2, which was
uniquely identified in dendritic cells, was mapped to a transmembrane domain-proximal cysteine. Inhibition of TLR2
S-palmitoylation pharmacologically or by cysteine mutagenesis led to decreased cell surface expression and a decreased
inflammatory response to microbial ligands.
Conclusions: This work identifies many fatty acylated proteins involved in fundamental cellular processes as well as cell
type-specific functions, highlighting the value of examining the palmitoyl proteomes of multiple cell types. S-
palmitoylation of TLR2 is a previously unknown immunoregulatory mechanism that represents an entirely novel avenue
for modulation of TLR2 inflammatory activity.
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Protein palmitoylation is the addition of a 16-carbon
fatty acid primarily to cysteines via a thioester linkage
(termed S-palmitoylation) [1]. This form of fatty acyl-
ation targets cytoplasmic proteins to membranes, but
can also occur on transmembrane proteins where it
often affects protein localization or stability [1-3]. Iden-
tification and characterization of palmitoylated proteins
has traditionally been encumbered because of insensi-
tive detection methods, the lack of a consensus amino
acid motif for bioinformatics prediction of palmitoyla-
tion sites, a lack of antibodies for detecting palmitoyla-
tion and challenges in detecting palmitoylated peptides
with standard mass spectrometry techniques [4,5]. To* Correspondence: yount.37@osu.edu
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unless otherwise stated.overcome these difficulties, non-radioactive chemical
tools and methodologies have been recently developed
that are advancing the study of protein palmitoylation
[6-11]. An analogue of palmitic acid possessing a ter-
minal alkyne group (alk-16, Figure 1A) is incorporated
by cells onto proteins at sites of palmitoylation [6]. The
alkynyl group allows a targeted reaction with azide-
functionalized detection tags via the copper-catalyzed
azide-alkyne cycloaddition reaction commonly termed
click chemistry (Figure 1A). Azido-rhodamine (az-rho)
is a detection tag that can be used for visualization,
while azido-azo-biotin (az-biotin) allows selective re-
trieval of alk-16-labeled proteins using streptavidin-
coated agarose [7,8,12]. We, and others, have previously
used, and continue to apply these tools for enhancing our
understanding of regulation of immune responses by lipid
post-translational modifications (PTMs) [7,11,13-17].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Identification of palmitoylated proteins in DC2.4 cells and MEFs. A) Schematic depicting alk-16 chemical reporter metabolic labeling of live
cells and subsequent reaction of cell lysates with detection tags for fluorescence visualization of palmitoylated proteins or affinity purification and
proteomic identification of palmitoylated proteins. B, C) Mock treated or IFNα treated DC2.4 cells and MEFS were labeled with alk-16 or DMSO as a control.
Lysates were subjected to click chemistry with azido-rhodamine (az-rho) (B) or azido-biotin (C). B) Proteins were separated by SDS-PAGE for fluorescence
gel scanning to visualize palmitoylome profiles. Anti-IFITM3 Western blotting served as a control for the activity of IFNα and anti-GAPDH blotting served as
a loading control. The red arrow points to the most prominent change in the banding pattern when comparing mock and IFNα treated samples.
C) Alk-16/azido-biotin labeled proteins enriched using streptavidin agarose were separated by SDS-PAGE, and were stained with coomassie blue for
visualization. Each lane was cut into slices for trypsin digestion and extraction of peptides for MS/MS identification. D) Venn diagram representing proteins
identified in C. After subtracting proteins identified in control lanes, 237 DC2.4 proteins and 438 MEF proteins were considered putative palmitoylated
proteins. The majority of identified proteins were known to be palmitoylated, including most proteins identified in both cell types and also many of those
specifically identified in either DC2.4 cells or MEFs (examples of each are shown in black text). The known IFN-induced and palmitoylated proteins IFITM3
and IRGM1 (blue text) were identified as upregulated in both IFNα-treated DC2.4 cells and MEFs. CD86 and TLR2 are example immunomodulatory proteins
specifically identified in DC2.4 cells, while NEDD4 is an example protein specifically identified in MEFs (red text). DMSO, dimethyl sulfoxide; IFITM3, interferon
(IFN)-induced transmembrane protein 3; IRFM1, immunity related GTPase M1; MEFs, murine embryonic fibroblasts; MS/MS, tandem mass spectrometry;
TLR2, Toll-like receptor 2.
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tools allowed the identification of palmitoylation-dependent
antiviral activity of the interferon (IFN)-induced transmem-
brane protein 3 (IFITM3) [7]. In the present study, we
performed an analysis of palmitoylated proteins in a murine
antigen presenting dendritic cell line (DC2.4) in compari-
son with murine embryonic fibroblasts (MEFs), both at
steady state and after IFNα treatment. Known lipidated and
IFN-induced proteins, IFITM3, bone marrow stromal anti-
gen 2 (BST2) and immunity related GTPase M1 (IRGM1),were detected in both cell types after IFNα treatment. We
also detected novel palmitoylated proteins expressed at
steady state, and validated several of these proteins,
including T-lymphocyte activation antigen CD86 and
Toll-like receptor 2 (TLR2) in dendritic cells (DCs), and
E3 ubiquitin-protein ligase NEDD4 in MEFs. Given the
complete novelty of the discovery of a lipid modification
occurring on a member of the extensively studied TLR
family, we chose to focus further on determining the ef-
fects of palmitoylation on TLR2.
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pathogens [18]. Their detection of microbial products re-
sults in activation of the transcription factor NF-κB and
production of inflammatory cytokines and other mediators
of the immune response [18]. At least 10 human and 11
mouse TLRs have now been identified, which recognize dis-
tinct sets of pathogen-associated molecules [19]. TLR2 is
expressed primarily on myelomonocytic cells including
antigen presenting cells, such as DCs and macrophages
[20]. TLR2 detects the widest range of microbial products
among the TLRs, including lipomannan from mycobacteria,
zymosan from yeast and bacterial lipopeptides typified by
the PamCSK synthetic lipopeptides [18,21]. As such, TLR2
knockout mice and humans with deleterious TLR2 poly-
morphisms are more susceptible to multiple pathogens
[22-26]. Thus, TLR2 is a critical component of the innate
immune system, and a better understanding of its post-
translational regulation may prove useful in our defense
against pathogenic organisms.Results and discussion
Visualization of palmitoylated proteins in MEFs
and DC2.4 cells
Having made the previous discovery of the critical role
of palmitoylation of IFITMs in the innate antiviral
immune response [7,14,15], we sought to determine
whether any additional IFN-induced proteins are regu-
lated by palmitoylation. For our experiments, we chose
to use murine antigen presenting cells (DC2.4) and
MEFs because these cell lines are responsive to type I
IFNs [14], are amenable to labeling with the alk-16 re-
porter of protein palmitoylation [6,14] and serve as a
control for one another in that type I IFN should induce
a similar set of proteins in both cell types. Additionally,
this analysis would provide a valuable comparison of the
general palmitoylomes of two cell types (myeloid and
non-myeloid) with unique functions. DC2.4 cells and
MEFs were either left untreated or were treated with
IFNα for four hours prior to metabolic labeling with
alk-16 in the presence or absence of IFNα for an
additional two hours. Cell lysates were reacted with az-
rho or az-biotin via click chemistry (Figure 1A). Az-rho-
labeled proteins were separated by SDS-PAGE and
visualized by fluorescence gel scanning (Figure 1B).
Anti-IFITM3 and anti-GAPDH blotting were used as
controls for the activity of IFNα on these cells and for
loading, respectively. The fluorescent profiles of the two
cell types did not indicate that drastic changes to palmi-
toylation occur upon IFNα treatment. However, one
specific band could be seen uniquely in the IFNα-
treated samples, appearing at approximately 15 kDa, po-
tentially corresponding to the molecular weight of the
IFITMs (Figure 1B).Mass spectrometric identification of palmitoylated
proteins in MEFs and DC2.4 cells
Given that differences induced by IFNα could possibly
be masked by highly abundant proteins within the fluor-
escent palmitoylome profiles observed in Figure 1B, we
next utilized the fraction of our samples that had been
reacted with az-biotin in order to affinity purify alk-16-
labeled palmitoylated proteins using streptavidin-coated
agarose. These purified proteins were separated by SDS-
PAGE (Figure 1C) and subjected to in-gel trypsin diges-
tion. Extracted peptides were then identified by tandem
mass spectrometry (MS/MS) analysis and assigned to
proteins using Mascot software. After subtraction of
proteins identified in the control lanes as described in
the Methods Section and eliminating proteins with
fewer than three spectral counts, a total of 247 proteins
were identified from the DC2.4 samples and 437 pro-
teins were identified from the MEF samples, indicating
that there is a large difference in the repertoire of palmi-
toylated proteins expressed by these different cell types
(see Additional file 1: Table S1, S2, Figure 1D). Of the
proteins identified in DC2.4 cells, 76% had been
previously identified as palmitoylated proteins in our
past analysis of this cell line, and by others in proteomic
studies of other cell types [7,16,17,27-31] (see Additional
file 1: Table S1). Of the proteins identified in MEFs, which
had not been palmitoylome profiled before, 64% were
previously reported to be palmitoylated, providing strong
validation of our methodology (see Additional file 1:
Table S2).
Analysis of several known palmitoylated proteins that
were identified uniquely in only one of the two cell types
would suggest that their differential detection is due to cell
type-specific expression differences. For example, sortilin-
1 (SORT1), inducible nitric oxide synthase (NOS2) and
HLA class II histocompatibility antigen gamma chain
(CD74) were uniquely detected in DC2.4 cells, consistent
with published data curated by BioGPS showing that
murine DCs express these genes while MEFs do not
[32-34] (Figure 1D). Conversely, catenin delta (CTNND1),
flotillin-2 (FLOT2), GTPase HRAS and tyrosine-protein
kinase YES were detected in MEFs, but not in DCs
(Figure 1D), again corresponding to cell type-specific ex-
pression patterns [32-34]. Further supporting the assertion
that the observed differences in the proteins detected are
not due to differences in the ability of the two cell types to
palmitoylate different subsets of proteins, BioGPS was also
utilized to examine the MEF and DC expression patterns
for the DHHC palmitoyltransferases (hereafter referred to
as DHHCs), the enzyme family responsible for the major-
ity of S-palmitoylation in cells [35,36]. Indeed, murine
MEFs and DCs each express nearly all of the DHHCs,
with the exception of DHHCs 11 and 19 which are testis-
specific and DHHC22 which is brain-specific [32-34].
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commonly identified in both MEFs and DC2.4 cells
We identified 121 alk-16-labeled proteins that were com-
mon to both DC2.4 cells and MEFs (listed in Additional
file 1: Table S3), suggesting that these proteins may per-
form fundamental cellular functions. These included crit-
ical cellular proteins such as calnexin (CANX), GTPase
NRAS and the cation-dependent mannose-6-phosphate
receptor (M6PR) (Figure 1D). Indeed, exploring the classi-
fication of these 121 proteins shows that proteins with en-
zymatic activity constituted 40% of the 121. Transporters
and ion channels formed another 20%. An additional 37%
constituted structural proteins and those in ubiquination
and glycosolation processes, with the remaining 3%
being cellular receptors and transcription regulators
(see Additional file 2: Figure S2A). Enrichment analysis
using Ingenuity defined pathways recapitulated that pal-
mitoylation is critical for a multitude of signaling
pathways, including those downstream of ephrin recep-
tors and integrins, as well as axonal guidance signaling
(see Additional file 1: Table S4). Similarly, pathways
centering on the cellular morphology-controlling small
GTPases, RAC1 and/or RHOA, involving multiple
palmitoylated proteins were identified (see Additional
file 1: Table S4).
On a more global level, network analysis of the 121
shared palmitoylated proteins demonstrated that the
MYC proto-oncogene protein and the cellular tumor
antigen p53 are upstream of 35 (29%) of these proteins,
which is more than would be expected by chance
(P <0.001, Additional file 2: Figure S2B). Several DHHCs
have been discovered to be misregulated in various tu-
mors, but their contribution to tumorigenesis is cur-
rently unclear [37]. Palmitoylated MYC and p53 effector
proteins may offer candidates for future experiments de-
termining the role of specific DHHCs and palmitoylated
proteins in cancer progression. Taken together, a multi-
tude of coherent pathways are regulated by palmitoyla-
tion in both DCs and MEFs, and these data add to our
growing appreciation of the roles palmitoylation plays in
regulating a myriad of basic cellular processes.
IFN-induced fatty acylated proteins
We also identified proteins present only in the IFNα-
treated samples or that had peptide peak area measure-
ments that were increased in the IFNα-treated samples by
at least 2.5 fold. Since type I IFNs generally induce a com-
mon set of antiviral proteins even in distinct cell types, we
reasoned that true IFN-induced palmitoylated proteins
should be present in the MS/MS results of both DC2.4
cells and MEFs. With this additional criterion, we were left
with only three proteins enriched in the IFNα-treated
samples in both cell types: IFITM3, IRGM1 and BST2,
also known as tetherin. Indeed, each of these proteins isknown to be IFN-inducible, and IFITM3 serves as a con-
trol since we expected to identify this protein based on
our past work [7]. Palmitoylation of IRGM1 was verified
in our laboratory (see Additional file 2: Figure S1), and
was also recently reported to be important for its mem-
brane localization and ability to affect mitochondria mem-
brane dynamics [38]. Interestingly, past palmitoylome
profiling studies of murine T cells [17] and human B cells
[16] also identified BST2 as a putative palmitoylated pro-
tein. Although BST2 palmitoylation has not yet been vali-
dated by visualization methods, the study performed in
murine T cells found that mass spectrometric detection of
alk-16-labeled BST2 was diminished upon sample treat-
ment with hydroxylamine, which cleaves thioester bonds
characteristic of palmitoylation [17]. Likewise, the work
identifying BST2 in B cells utilized acyl-biotin exchange
chemistry, which allows specific enrichment of S-acylated
proteins [16]. BST2 is also well characterized to be lipi-
dated with a GPI anchor [39], which could incorporate
long chain fatty acids such as alk-16, although previous
alk-16 proteomic profiling studies have not been signifi-
cantly contaminated with GPI anchored proteins, arguing
against this possibility [7,9,11,17,27]. Mutation of individ-
ual residues within BST2 will be necessary to determine
the precise location and type of lipidation reported by alk-
16 labeling. Nonetheless, our data confirm that the IFN-
induced effector proteins, IFITM3, IRGM1 and BST2, are
each lipid-modified.
Novel palmitoylated proteins identified in MEFs and
DC2.4 cells
Our work identified 168 proteins in MEFs and 59 pro-
teins in DC2.4 cells that had not been previously re-
ported to be palmitoylated in past proteomic studies
(see Additional file 1: Table S1, S2). Many of these pro-
teins were found in only one of the two cell types. For
example, we observed the E3 ubiquitin-protein ligase
NEDD4 specifically in MEFs (Figure 1D), and confirmed
its palmitoylation, thereby identifying an entirely new
modification with potential regulatory activity on this
extensively studied and critically important protein
[40,41] (see Additional file 2: Figure S3). Of particular
interest to our laboratory were two proteins uniquely
identified in DC2.4 cells that are essential to immune re-
sponses, CD86 and TLR2. CD86 is expressed on the sur-
face of mature DCs and provides a costimulatory signal
to T cells that is necessary for their proper activation
[42]. We thus sought to confirm CD86 palmitoylation
and map its site of modification. Utilizing a C-terminally
HA-tagged construct of murine CD86 (CD86-HA), we
were able to validate our MS/MS results by demonstrat-
ing robust labeling of CD86-HA with alk-16 (Figure 2A).
Interestingly, palmitoylated CD86-HA was observed as
multiple high MW bands indicating that its glycosylated
Figure 2 Confirmation of the S-palmitoylation of immunomodulatory proteins, CD86 and TLR2. A-C) Validation and mapping of CD86 and TLR2
palmitoylation. HEK293T cells were transfected with the indicated CD86-HA (A), FLAG-TLR2 (B), or TLR2-YFP (C) constructs. Transfected cells were labeled
with 50 uM alk-16 or DMSO as a control for one hour. Cell lysates were subjected to immunoprecipitation for the respective epitope tag or fluorescent
protein. Immunoprecipitates were reacted with azido-rhodamine (az-rho) for visualization of palmitoylation by fluorescent gel scanning. Western blotting
was performed to confirm comparable protein loading. D,E) Overexpression screens to identifiy DHHCs capable of modifying CD86-HA and FLAG-TLR2.
HEK293T cells were co-transfected with HA-tagged DHHCs 1 to 23 or GST as a control and either CD86-HA (D) or FLAG-TLR2 (E). Immunoprecipitated
proteins were treated and visualized as in A-C. Western blotting was performed to confirm comparable protein loading. Bar graphs represent average
quantified fluorescence intensities from at least three identical experiments normalized to their respective western blots. Values for CD86 or TLR2
co-transfected with GST control were set to 1. DHHC constructs are labeled according to previously used DHHC nomenclature in order to be consistent
with past studies using these constructs. Importantly, DHHCs 2, 3, 6, 7 and 15 are the same in both the previous and modern nomenclature. Note that in
D, DHHC14 itself is visible in the fluorescent gel scan of this region. The expression levels of the individual DHHCs obtained in a representative experiment
are shown in Additional file 2: Figure S6. DMSO, dimethyl sulfoxide; TLR2 Toll-like receptor 2.
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form at the expected molecular weight of 35 kDa was not
modified, potentially suggesting sequential modification(Figure 2A). Mutation of Cys-264 to Ala at the cytoplas-
mic edge of the CD86 transmembrane domain resulted in
a complete loss of alk-16 labeling, implicating Cys-264 as
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CD86 has homology to, and a partially redundant function
with, T-lymphocyte activation antigen CD80 [44]. We thus
generated a CD80-HA construct and also confirmed its
palmitoylation (see Additional file 2: Figure S4), thereby
demonstrating a conservation of this PTM on the CD80
and CD86 costimulatory molecules.
We similarly confirmed TLR2 palmitoylation utilizing a
previously generated construct in which the human TLR2
ER signal sequence was replaced by an artificial signal se-
quence followed by a FLAG epitope tag [45,46]. Indeed,
FLAG-TLR2 was readily labeled by alk-16 (Figure 2B).
Two cytoplasmic-facing cysteines within TLR2, Cys-595
and Cys-596, were predicted by the CSS-Palm version 3.0
palmitoylation site prediction program [47] to be highly
probable sites of palmitoylation. Generating Cys to Ala
mutations at these positions and at the nearby Cys-609
allowed for the demonstration that palmitoylation is lost
only when Cys-609 is mutated (Figure 2B). Thus, while
bioinformatic methods may provide candidate sites of
modification, the study of protein palmitoylation requires
empirical validation. We further confirmed that Cys-609
is the primary site of human TLR2 S-palmitoylation using
a TLR2 construct with its natural ER signal sequence and
a C-terminal YFP tag [48,49] (Figure 2C), and also verified
that murine TLR2 is S-palmitoylated on the same residue
(see Additional file 2: Figure S5).
To determine the extent to which palmitoylation is con-
served on TLRs other than TLR2, we tested a panel of hu-
man TLRs 1 to 10 for alk-16 labeling in HEK293T cells.
While the expression levels of the different TLRs varied,
TLR2, TLR5 and TLR10 clearly showed palmitoylation sig-
nals above background bands (see Additional file 2:
Figure S5). Interestingly, TLR10, which physically interacts
with TLR2 and has been associated with regulating TLR2
responses (43, 44), had the strongest palmitoylation signal
relative to its total protein level (see Additional file 2:
Figure S5). These findings reveal that palmitoylation is at
least partially conserved on a subset of the human TLRs.
These data also confirm that palmitoylation of transmem-
brane proteins occurs with specificity that is not currently
predictable by sequence analysis or by homology with
known palmitoylated proteins.
Palmitoylation of CD86 and TLR2 can be increased by
specific DHHCs
In order to examine whether or not S-palmitoylation of
CD86 and TLR2 could be installed by specific DHHCs, we
performed overexpression screens of each of the DHHCs
with CD86 and TLR2. This method is commonly used to
identify DHHCs capable of modifying individual protein
substrates [35,50-53]. CD86-HA S-palmitoylation was in-
creased by DHHCs 2, 3, 6 and 7 (Figure 2D, Additional file
2: Figure S7). FLAG-TLR2 S-palmitoylation was similarlyenhanced by the DHHCs 2, 3, 6 and 7 (Figure 2E,
Additional file 2: Figure S7). Since the palmitoylation sites
of CD86 and TLR2 are both at the cytoplasmic edge of
their respective transmembrane domains, this may suggest
that this subset of DHHCs is particularly adept at modify-
ing cysteines adjacent to membranes. However, unlike
CD86, palmitoylation of TLR2 was also increased by
DHHC15, demonstrating substrate specificity for individ-
ual DHHCs (Figure 2E). Overall, these experiments fur-
ther validate that CD86 and TLR2 are S-palmitoylated
proteins whose modification can be mediated enzymati-
cally by specific DHHCs.
Palmitoylation is required for complete activation of
NF-κB by TLR2
Given our laboratory’s focus on innate immunity, we chose
to further investigate the effects of S-palmitoylation on the
activity of TLR2 in primary cultured DCs. For these experi-
ments, we utilized a commonly used covalent inhibitor of
DHHCs, 2-bromopalmitate (2-BP) [54]. We found that 2-
BP treatment of murine bone marrow-derived (BM) DCs re-
sulted in a loss of the endogenous TLR2 S-palmitoylation
signal (Figure 3A). Concomitantly, 2-BP-treated BMDCs lost
the ability to produce high levels of the pro-inflammatory
cytokines IL-6 and TNFα in response to Pam3CSK4 and
lipomannan, which are microbe-based ligands specifically
detected by TLR2 (Figure 3B). Since prolonged exposure to
2-BP can result in off-target effects and cellular toxicity
[55,56], we also employed Sendai virus, a TLR-independent
activator of cytoplasmic RIG-I-like receptors, as a control
[57-61]. Sendai virus induced high levels of IL-6 and TNFα
secretion even in the presence of 2-BP (although TNFα was
partially affected), indicating that the effects of 2-BP were
largely specific to the TLR2 pathway (Figure 3B). Addition-
ally, we did not observe overt cellular toxicity upon 2-BP
treatment in the time period examined, as judged by Try-
pan blue exclusion. Treatment with 2-BP also inhibited
lipomannan-induced IL-6 and TNFα secretion from pri-
mary human monocyte-derived DCs (see Additional file 2:
Figure S8). Thus, the inhibition of cellular palmitoylation
by 2-BP leads to an impaired TLR2-dependent proinflam-
matory cytokine response by DCs.
We next measured the ability of TLR2-YFP and TLR2-
C609A-YFP to stimulate NF-κB-dependent gene expression
in response to microbial ligands. TLR2-C609A-YFP was
significantly less able than TLR2-YFP to induce NF-κB-
dependent luciferase production in response to Pam3CSK4,
lipomannan and zymosan (Figure 3C). Levels of WT and
mutant TLR2 were comparable in these experiments
as measured by Western blotting (Figure 3D). Similar results
demonstrating a defect in the induction of NF-κB-
dependent luciferase activity by the palmitoylation-deficient
TLR2-C609A mutant were also obtained when utilizing
FLAG-tagged constructs, and further demonstrated that this
Figure 3 TLR2 S-palmitoylation is necessary for NF-kB-dependent gene induction and cytokine production in response to TLR2 microbial
ligands. A) TLR2 S-palmitoylation is inhibited by 2-BP in BMDCs. Cells were treated with 100 uM 2-BP or an equivalent volume of DMSO for eight hours
prior to labeling for one hour with 50 uM alk-16. TLR2 was immunoprecipitated from cell lysates and reacted with az-rho for fluorescence visualization of
palmitoylation. Western blotting with anti-TLR2 antibodies was performed to confirm comparable protein loading. B) Cytokine secretion in reponse to
TLR2 ligands is inhibited by 2-BP in BMDCs. Cells were treated with 100 uM 2-BP or an equivalent volume of DMSO for eight hours. TLR2 ligands, Pam3CSK4
(2 ug/mL) or lipomannan (4 ug/mL), or Sendai virus (SeV) (MOI 5), were added to the cellular media for an additional six hours. IL-6 and TNFα levels in
cellular supernatants were measured by ELISA. Results in A,B are representative of three experiments. Error bars in B are the standard deviation of triplicate
samples. C) Palmitoylation-deficient TLR2 is less able than WT to induce NF-κB-dependent gene expression in response to microbial ligands. HEK293T cells
were co-transfected with the indicated plasmids along with a reporter construct expressing NF-κB-driven firefly luciferase and a plasmid constitutively
expressing renilla luciferase for normalization. Cells were mock treated or treated for eight hours with Pam3CSK4 (2 ug/mL), lipomannan (4 ug/mL) or
zymosan (10 ug/mL), and luciferase activity was measured in cell lysates. Results are presented as fold induction over mock treated samples. D) Western
blots confirming similar expression of TLR2-YFP and TLR2-C609A-YFP in experiments performed in C. Results in C, D are representative of at least five
experiments. Error bars in C represent standard deviation of triplicate samples. *P <0.001 by Student’s t-test. az-rho, azido-rhodamne; BMDCs, bone marrow
dendritic cells; DMSO dimethyl sulfoxide; TLR, Toll-like receptor; 2-BP, 2-bromopalmitate.
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palmitoylation site since a Cys-596 to Ala mutant possessed
activity similar to WT FLAG-TLR2 (see Additional file 2:
Figure S9). In sum, our data demonstrate that the TLR2
Cys-609 S-palmitoylation site is required for proper activa-
tion of NF-κB in response to microbial ligands.
S-pamitoylation of TLR2 promotes its cell surface
localization
We next examined the effect of endogenous TLR2 ligation
on its S-palmitoylation status. We observed that TLR2
palmitoylation is decreased upon stimulation of murine
BMDCs with lipomannan (Figure 4A,B). This palmitoylation
decrease correlates with a decrease in TLR2 surface staining,
while surface staining of costimulatory molecules and MHC
II increased as expected for activated DCs (Figure 4C). This
finding is also consistent with past observations of TLR2downregulation at the cell surface upon binding of its
ligands [62-64]. The correlation between decreased TLR2 S-
palmitoylation and decreased cell surface levels suggested
that, perhaps, S-palmitoylation affects TLR2 localization.
Indeed, inhibition of palmitoylation with 2-BP decreased en-
dogenous TLR2 surface staining of BMDCs, while overall
cellular levels of TLR2 remained similar (Figure 4D). In
accord with these results, overexpressed murine FLAG-
TLR2-C609A showed a subtle, but reproducible, decrease in
cell surface staining when compared to WT FLAG-TLR2
(Figure 4E), with their mean fluorescence intensities differ-
ing by approximately 25% on average (Figure 4F). Import-
antly, achieving robust cell surface staining of FLAG-TLR2
constructs required transfection of five to ten times more
DNA than was required for activity assays, perhaps suggest-
ing that the forced overexpression of the WT and C609A
TLR2 constructs results in underestimation of their cell
Figure 4 S-palmitoylation promotes TLR2 cell surface expression. A-C) BMDCs were mock treated or treated with 4 ug/mL lipomannan for
24 hours. A) Cells were labeled with 50 uM alk-16 for one hour. Immunoprecipitated TLR2 was reacted with az-rho for visualization of palmitoylation.
Anti-TLR2 Western blotting confirmed comparable protein loading. B) Fluorescent gel scans from four experiments as in A were quantified and
normalized to their respective Western blots. Values for lipomannan were normalized relative to a value set to 1 for mock, and were averaged. The
error bar represents the standard deviation of four experiments. *P <0.001 by Student’s t-test. C) Cells were stained with antibodies against the
indicated surface proteins and analyzed by flow cytometry. Results in C are representative of at least three experiments. D) BMDCs were treated with
100 uM 2-BP or solvent control for 12 hours, and stained with anti-TLR2 antibody for flow cytometry analysis of TLR2 surface levels, or were lysed and
subjected to anti-TLR2 Western blotting to examine total TLR2 levels. Anti-GAPDH blotting served as a loading control. Results in D are representative
of at least three similar experiments. E, F) MEFs were transfected with plasmids expressing murine FLAG-TLR2 (WT), FLAG-TLR2-C609A (C609A), or
vector control. E) Cells were subjected to anti-TLR2 staining for flow cytometry analysis of TLR2 surface expression or were lysed for western blotting
with anti-FLAG antibodies for comparing total TLR2 protein levels. Anti-GAPDH Western blotting was performed as a loading control. F) Flow
cytometry results from three experiments as in E were quantified in terms of mean fluorescence intensity (MFI). Values for C609A were normalized
relative to a value set to 1 for WT, and were averaged. The error bar represents the standard deviation of three experiments. *P <0.01 by Student’s
t-test. az-rho, azido-rhodamne; BMDCs, bone marrow dendritic cells; MEFs, murine embryonic fibroblasts; TLR, Toll-like receptor.
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tein levels and the stability of TLR2 are not affected by pal-
mitoylation by performing pulse-chase analysis of FLAG-
TLR2 and FLAG-TLR2-C609A, which demonstrated that
the decay of the WT and mutant proteins was similar
(see Additional file 2: Figure S10). Overall, we conclude that
S-palmitoylation positively regulates TLR2 activity, at least
in part, by promoting its trafficking to the cell surface.
Conclusions
The development of chemical proteomic methods to iden-
tify palmitoylated proteins has led to a tremendous in-
crease in our appreciation of the numerous ways in which
palmitoylation regulates key cellular processes and can
control cell type-specific pathways [7,9,11,16,17,28-31,65].
We previously reported the identification of 157 palmitoy-
lated proteins in DC2.4 cells that included proteins critical
to antiviral immune responses [7]. However, the absence
of several expected palmitoylated proteins from our MS/
MS identification led us to hypothesize that additional un-
known palmitoylated proteins also remained to be identi-
fied in this cell type [13]. Indeed, refinements to our
palmitoylated protein enrichment protocol that included
increased incubation time with streptavidin agarose and
repeated washing steps, along with updates to our mass
spectrometry capabilities, have led to a deeper coverage of
the DC2.4 palmitoylome (Figure 1 and Additional file 1:Table S1). In comparison to the palmitoylome of MEFs,
we identified novel putative palmitoylated proteins that
play a role in the immune functions of DCs. Following up
on several of these proteins, we were able to validate pal-
mitoylation of the CD80 and CD86 costimulatory mole-
cules (Figure 2A and Additional file 2: Figure S4) as well
as TLR2 (Figure 2B,C and Additional file 2: Figure S5).
Interestingly, our proteomic results indicated that MEFs
express a wider diversity of palmitoylated proteins than
DCs (Figure 1D and Additional file 1: Table S1, S2), and
include many proteins, such as NEDD4, that should lead
to exciting follow up studies.
Our discovery of CD80, CD86 and TLR2 palmitoylation
in DCs reveals novel mechanisms of immune regulation,
and underscores the value of examining palmitoylation in
diverse cells types. CD80 and CD86 are essential for
immune responses to most pathogens as well as for elimin-
ation of tumor cells by the immune system [66]. These
costimulatory molecules provide a second signal for T-cell
activation in addition to MHC/peptide complexes pre-
sented on the surface of mature DCs [66]. Future studies
will aim to determine whether palmitoylation is involved in
the trafficking of these molecules to the DC surface, their
subsequent clustering at the immunological synapse and
their impact on immune function.
Here, we specifically followed up on the role of
S-palmitoylation in regulating TLR2 activity. Indeed, the
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was decreased in the absence of TLR2 S-palmitoylation, in-
dicating that this lipid modification is a positive regulator of
TLR2 activity (Figure 3 and Additional file 2: Figure S8, S9).
S-palmitoylation is necessary for complete localization of
TLR2 at the cell surface, and thus likely affects its interac-
tions with its ligands (Figure 4D-F). While an effect of
palmitoylation on the cell surface expression of multiple
other proteins has been previously reported [3], it is
interesting to note that although CD86 and TLR2 are
both S-palmitoylated at membrane-proximal cysteines
(Figure 2A-C) by a similar subset of DHHCs (Figure 2D,E),
their cell surface localization is inversely regulated during
DC activation (Figure 4B). This reinforces the commonly
observed theme that palmitoylation can have unpredictable
effects depending on the protein context in which it occurs
[1,3,67]. Future analyses of how S-palmitoylation of
additional immune receptors controls their localization, in-
teractions and signaling will be an exciting area of future
study, as will the examination of potential subversion of
TLR2 S-palmitoylation by pathogens. Importantly, the
identification of S-palmitoylation of TLRs suggests that this
reversible form of protein lipidation [68] may be targeted in
the future to manipulate beneficial and non-beneficial
TLR2-mediated immune responses.
Methods
Click chemistry, fluorescence gel scanning, and proteomic
identification of palmitoylated proteins
Click chemistry was performed as previously described
[6-8,69]. In short, immunoprecipitated proteins or cell ly-
sates were reacted for one hour at room temperature with
100 μM azido-rhodamine [6] or azido-azo-biotin [12],
1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP),
100 μM tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine
(TBTA), and 1 mM CuSO4 · 5H2O. In-gel fluorescence scan-
ning was performed using a Typhoon 9400 imager (Amer-
sham Biosciences, Amersham, United Kingdom) (excitation
532 nm, 580 nm detection filter). Enrichment of alk-16-
labeled proteins was performed according to a standard
protocol [7-9] with minor adjustments in the amount of
protein and buffers used and the number of washing steps,
in order to increase specificity and recovery of labeled pro-
teins. Proteins in cell lysates reacted with azido-azo-biotin
were methanol precipitated at −20°C overnight, washed with
ice-cold methanol three times, dried, and resolubilized in
SDS buffer (4% SDS, 150 mM NaCl, 50 mM triethanola-
mine, pH 7.4). A total of 2.5 mg of the resolubilized protein
in 1 mL was diluted to 15 mL with PBS containing 1% Brij-
97 and was incubated with 100 μL of pre-washed high-
capacity streptavidin agarose (Thermo Scientific, Waltham,
Massachusetts, United States) at 4°C on a nutating mixer
overnight. The streptavidin agarose was then washed five
times with 15 mL PBS containing 1% SDS followed by threewashes with 15 mL PBS and two washes with 250 mM am-
monium bicarbonate. Cysteines were then capped with
iodoacetamide, followed by three additional washes with
250 mM ammonium bicarbonate. Proteins were eluted
from the agarose three times using sodium dithionite, and
concentrated using low molecular weight Centricons
(Millipore, Billerica, Massachusetts, United States) as previ-
ously described [8]. Proteins were then separated by SDS-
PAGE for in-gel digestion, peptide extraction and MS/MS
analysis. MS/MS was performed by the Rockefeller Univer-
sity Proteomics Resource Center on a Thermo LTQ-
Orbitrap mass spectrometer that had undergone recent
professional tuning and alignment, and that was equipped
with a Dionex 3000 capillary/nano HPLC. MS/MS spectra
of peptides were analyzed against the mouse protein data-
base using the Mascot version 2.3 search tool. Data from
samples analyzed by Mascot were compared with Proteo-
meDiscoverer software (Thermo Scientific) utilizing a cut-
off score of 40 and a requirement of two peptides per
protein. Data were then further manually analyzed by elim-
inating proteins that were identified with less than a 20-
fold detection increase over the controls based on the
ProteomeDiscoverer software peptide peak area measure-
ment, and by eliminating proteins with a sum of less than
three spectral counts in the alk-16-treated samples. Prote-
omic lists from other studies were compared with this data
set using gene symbols obtained, if necessary, by converting
published identifiers into gene symbols using the UniProt
database along with the DAVID Gene ID Conversion Tool
(National Institute of Allergy and Infectious Diseases,
National Insttutes of Health (NIAID, NIH)).
Pathway enrichment and network analysis
Protein data from DC2.4 and MEF cells with suitable qual-
ity as described above were standardized using GenPept ac-
cession numbers. Overlapping proteins were subsequently
ported into Ingenuity IPA software [70]. Canonical pathway
enrichment was performed using IPA defined classes and
corrected for multiplicity using the Benjamini-Hochberg
method. Network analysis and subsequent diagrams were
generated using only direct associations among the pro-
teins. P-values for upstream analysis were calculated using
the Fisher’s exact test.
DNA constructs and luciferase assays
TLR2-YFP, pCDNA3-YFP and fluorescent protein-tagged
constructs for the other human TLRs were obtained from
Addgene (plasmids 13014, 13033, 13016, 13641, 13018,
13019, 13020, 13022, 13024, 13642, and 13643, deposited
by Doug Golenbock). The human FLAG-TLR2 construct
was also obtained from Addgene (plasmid 13082, deposited
by Ruslan Medzhitov), as was the mouse FLAG-TLR2 con-
struct (plasmid 12291 deposited by Bruce Beutler [71]).
CD80 and CD86 coding sequences were amplified by PCR
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as well as EcoRI and BglII restriction sites for insertion into
the pCAGGS expression vector. IRGM1 coding sequence
was amplified by PCR from DC2.4 cell cDNA incorporating
SalI and XhoI restriction sites for in-frame insertion into
the pCMV-HA expression vector. The QuikChange Multi-
Site Directed Mutagenesis Kit from Stratagene (La Jolla,
California, United States) was used for cysteine mutagen-
esis. HA-tagged DHHCs and GST control plasmids were
kindly provided by Masaki Fukata (NIPS, Okazaki, Japan).
For luciferase assays, a NF-kB-dependent firefly luciferase
reporter construct provided by Dimitris Thanos (Biomed-
ical Sciences Research Center, Athens, Greece) was used
along with the pRL-TK plasmid (Promega, Madison,
Wisconsin, United States) driving constitutive expression of
Renilla luciferase. The Dual Luciferase Reporter Assay Sys-
tem from Promega was used for detection of firefly and
Renilla luciferase. Mycobacterium smegmatis lipomannan,
zymosan and Pam3CSK4 were purchased from InvivoGen
(San Diego, California, United States). Sendai virus strain
Cantell was grown in 10-day embryonated chicken eggs
and titered as previously described [72].
Cell culture and flow cytometry
DC2.4, MEFs, and HEK293T cells were grown in DMEM
supplemented with 10% FBS in a 37°C humidified incuba-
tor with an atmosphere of 5% CO2. BMDCs were generated
by culturing bone marrow cells for 7 days in RPMI supple-
mented with 10% FBS, 10 ug/mL gentamicin and 25 ng/
mL GMCSF, with media changes on days 3 and 5. Non-
adherent cells were used for experimentation and were vali-
dated to be DCs based on 70% to 80% of the cells staining
positive for CD11c and MHCII as measured by flow cytom-
etry. Murine IFNα was purchased from eBioscience (San
Diego, California, United States). All flow cytometry stain-
ing was performed after a 10-minute incubation in ice cold
PBS with Fc receptor block (BD Biosciences, San Jose,
California, United States). Antibodies from BD Biosciences
directed at the following molecules were used at 1:200 dilu-
tion in ice cold PBS for 20 minutes at 4°C: CD11c
(#557400), MHCII (#553552), CD80 (#553769), CD86
(#553691) and TLR2 (#562625). All samples were washed
three times with ice cold PBS, read on a BD FACSCanto II
flow cytometer and analyzed using Flowjo software. For
flow cytometry of transfected MEFs, cells were detached
from plates by incubating in PBS/10 mM ethylenediamine-
tetraacetic acid (EDTA) for 20 minutes at 37°C.
Transfections, metabolic labeling, cell lysis,
immunoprecipitations, and Western blotting
HEK293T cells were transfected overnight at 60% con-
fluency using Lipofectamine 2000 (Life Technologies,
Carlsbad, California, United States) according to the man-
ufacturer’s instructions. For TLR2 activity experiments,100 ng of TLR2-expressing plasmids were transfected into
wells of a 12-well plate along with 1 ug of NF-κB lucifer-
ase reporter plasmid and 50 ng of pRL-TK. For all other
experiments, 1 ug or 2 ug of plasmid was transfected for
12-well and 6-well plates, respectively. For cell labeling,
alk-16 was added to 37°C DMEM containing 2% charcoal/
dextran-filtered fetal bovine serum for a final concentra-
tion of 50 uM. For mock-labeled samples, an equivalent
volume of DMSO rather than alk-16 solution was added
to the labeling media. After replacing the media, labeling
was allowed to proceed for one to two hours under stand-
ard culture conditions at 37°C or for four hours for prote-
omic experiments. 2-BP was purchased from Sigma-
Aldrich (St. Louis, Missouri, United States), prepared fresh
in DMSO for each experiment and used at a concentra-
tion of 100 μM. For all alk-16 labeling experiments, cells
were washed twice with room temperature PBS and pel-
lets were flash-frozen with liquid nitrogen for storage at
−80°C. Cell pellets were lysed with Brij97 buffer (1% Brij
97, 150 mM NaCl, 50 mM triethanolamine, pH 7.4) and
cellular debris was cleared by centrifugation for five mi-
nutes at 1,000 x g. For immunoprecipitations, anti-FLAG
or anti-HA conjugated agarose (Sigma), or anti-GFP anti-
body (JL-8, Clontech, Mountain View, California, United
States) or anti-TLR2 antibody (MAb-mTLR2, InvivoGen,
San Diego, California, United States) with protein G agar-
ose (Roche Diagnostics, Indianapolis, Indiana, United
States) was used. Western blots for FLAG-tagged proteins
were performed with anti-FLAG antibody produced in
rabbit (Sigma-Aldrich, St. Louis, Missouri, United States) at
a 1:1,000 dilution. Blots for HA-tagged proteins were
performed using a polyclonal antibody preparation from
Clontech at a 1:1,000 dilution. Blots for fluorescent protein-
tagged TLRs were performed with Clontech mouse mono-
clonal anti-GFP (JL-8) at a 1:2,500 dilution and blots for
endogenous mouse TLR2 was performed with anti-TLR2
(MAB1530) from R&D Systems (Minneapolis, Minnesota,
United States) at a 1:1,000 dilution.Availability of supporting data
MS/MS raw data files have been uploaded to the Pep-
tide Atlas data repository and are freely available for
download and analysis. Files for DC2.4 samples can be
accessed at PeptideAtlas under dataset identifier
PASS00594 [73]. These files correspond to gel slices cut
from the first four lanes of Figure 1C. Specifically, files 1
to 7 are from lane 1 (DMSO treated cells), files 8 to 14
are from lane 2 (IFN alpha/DMSO treated cells), files 15
to 21 are from lane 3 (alk-16 treated cells), and files 22
to 28 are from lane 4 (IFN alpha/alk-16 treated cells).
Files for MEF samples can be accessed at PeptideAtlas
under dataset identifier PASS00595 [74]. These files cor-
respond to gel slices cut from lanes 5 through 8 of
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http://www.biomedcentral.com/1741-7007/12/91Figure 1C. Specifically, files 29 to 35 are from lane 5
(DMSO treated cells), files 36 to 42 are from lane 6 (IFN
alpha/DMSO treated cells), files 43 to 49 are from lane
7 (alk-16 treated cells), and files 50 to 56 are from lane 8
(IFN alpha/alk-16 treated cells).Additional files
Additional file 1: Table S1: Alk-16-labeled proteins identified from
DC2.4 cells. Table S2: Alk-16-labeled proteins identified from MEFs. Table S3:
Palmitoylated proteins identified in both DC2.4 cells and MEFs. Table S4:
Molecular pathway enrichment of palmitoylated proteins found in both
MEFs and DC2.4 cells.
Additional file 2: Figure S1: Confirmation of IRGM1 palmitoylation.
Figure S2: Ingenuity pathway analysis of palmitoylated proteins
identified in both DC2.4 cells and MEFs. Figure S3: Confirmation of
NEDD4 palmitoylation. Figure S4: Identification of CD80 palmitoylation.
Figure S5: Murine (m) TLR2 is S-palmitoylated on Cys-609. Figure S6:
Partial conservation of palmitoylation occurring on the human TLRs.
Figure S7: Expression levels of HA-tagged DHHC constructs. Figure S8:
TLR2-dependent cytokine responses are decreased by chemical inhibition of
palmitoylation in primary human DCs. Figure S9: TLR2 S-palmitoylation is
required for NF-kB-dependent gene induction.Figure S10: S-palmitoylation
of TLR2 does not affect its stability.Competing interests
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